drugset / Trial / NCT01294436

Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

NCT01294436

Phase 3 Completed 728 enrolled AstraZeneca Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who have inadequate blood sugar control on diet and exercise or on other anti-diabetic treatment will be included in this study.

Timeline

Start
2011-02
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 5 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral